Investigations into how DUX4 drives FSHD pathology have largely focused on the expression of DUX4 target genes, some of which have been demonstrated to be anti-myogenic (17–19) and pro-apoptotic (20–22). The gene discussed is DUX4; the disease is facioscapulohumeral muscular dystrophy.